Dr Annalisa Morgan reflects on new data on DMTs for RRMS that highlighted the potential of BTK inhibitors such as ...

Tolebrutinib is more effective in reducing the risk of disability progression in MS patients with paramagnetic rim lesions, ...

Combining genetic and symptom-based risk scores to predict MS may accelerate the diagnosis of the disease, according to a new ...

Dr Annalisa Morgan previews discussions on disease-modifying therapies, emerging treatments such as CAR T-cell therapy, and ...

A post-hoc analysis of phase 3 trials presented at ACTRIMS Forum 2025 suggests that tolebrutinib may be more effective in MS ...

Tolebrutinib had the most protective effect against disability worsening at 6 months in patients with multiple sclerosis who had a greater number of MRI paramagnetic rim lesions at baseline, data show ...

A six-month modified Atkins diet intervention in relapsing multiple sclerosis patients led to significant immunometabolic ...

A 6-month ketogenic diet and 2-month calorie-restricted diet were associated with significant reductions in biological age in ...

Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis – Vidofludimus Calcium’s Activation of Nurr1 Reduces ...

Alumis Inc., a clinical stage biopharmaceutical company, announced that it will present data on its oral therapy A-005, a selective TYK2 inhibitor, at the ACTRIMS Forum 2025 on February 28 ...

TG Therapeutics will present data on BRIUMVI for relapsing multiple sclerosis at the ACTRIMS forum, February 27 – March 1, 2025. $TGTX insiders have traded $TGTX ...

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced ...